Overview of 
The William Herron Hall
Rare Lymphoma Program 

Because of our Generous Supporters, ICAN patients involved in
The William Herron Hall Rare Lymphoma Program
have access to the following information services:

  • A review and analysis of the patient's pathology report relating to TNM staging ("Tumor Node Metastasis"); review of the patient's medical history, diet, lifestyle and risk factors, current condition as well as any comorbid factors; and complete review of symptoms prior to presentation.
  • Referrals, at the patient contact's request, to medical oncologists, radiation oncologists, surgical oncologists, radiologists, interventional radiologists, anesthesiologists, and additional specialists relevant to the patient's ongoing care.
  • Referrals to support groups that may be of assistance in handling the emotional impact that cancer has on the patient and the patient's family.
  • Referrals to cancer-specific organizations that may be of assistance in addressing insurance issues or employment termination issues (because of diagnosis or disclosure of metastatic disease).
  • Review of the nature/amelioration of specific side effects from chemotherapy (such as nausea and neuropathy) as well as from other treatment modalities.
  • Discussion of the interaction of diet and cancer chemotherapy drugs based on recent studies.
  • Delineation of the symptoms about which the patient should alert his/her oncologist.
  • Discussion of relevant imaging technology.
  • Discussion of pain management issues and treatment options that can be addressed with the patient's medical team.
  • Explanation of the recommendations given or not given by the patient's physicians; assistance in answering the patient's questions which remain either after or between appointments with the medical team.
  • Review of the relevant radiotherapy/interventional radiology options which the patient contact, in turn, may discuss with his/her medical team.
  • Review the patient’s genomics, proteomics, transcriptomics, and immune cell studies to best prioritize clinical trial options and sequencing of therapies.
  • Analysis of relevant cancer clinical trials options as well as the nature and purpose of clinical trials using Remission Coach®.
  • Review of relevant cancer-specific drugs in the anticancer pipeline.
  • Review of all relevant and complementary and alternative medicine ("CAM") avenues.
  • Review of the merits of filing a "Single Patient IND for Compassionate or Emergency Use" for a specific experimental cancer drug, if relevant to the patient's situation.
  • Exploration of options that might reduce travel costs for the patient contact, such as Corporate Angels Network, as well as ICAN supporters who have volunteered to host a clinical trials patient in a particular city.

separator

The William Herron Hall Rare Lymphoma Program
is a vital part of ICAN's Cancer Patient Advocacy and Clinical Trials Program Advocacy Services.

For more information about this special program, please click on.....

  1. Main
  2. Photos
  3. Inspiration
  4. Memories
  5. Literature

Donate

ICAN is currently working on The William Herron Hall Rare Lymphoma Program. We are working to put together a Family and Friends Advisory Council for the The William Herron Hall Rare Lymphoma Program. If interested, please email us at William.Hall.Program@askican.org.

If you would like to become involved as a donor and supporter or a member of our Cancer Research Literature team as a Research Team Leader (medical school students, physicians, nurses, and post-docs only please), you may reach us at William.Hall.Program@askican.org.




Federal Tax I.D.: EIN 86-0818253 | WA Charities: 37195